Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II study of pemetrexed and cisplatin as either induction or adjuvant chemotherapy in stage IB-II non-small cell lung cancer.

Next Previous
Trial Profile

Randomized phase II study of pemetrexed and cisplatin as either induction or adjuvant chemotherapy in stage IB-II non-small cell lung cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 26 Jul 2012 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
  • 31 Aug 2009 Status changed from active, no longer recruiting to discontinued.
  • 01 Aug 2009 Results have been presented at the 13th World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top